Updates in Immunotherapy for Non–Small Cell Lung Cancer - Episode 8

Second-Line Therapy for Stage IV NSCLC

, , , , ,

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.